The first non-surgical repair for Pelvic Organ Prolapse
Pelvic Organ Prolapse (POP) affects nearly 50% of women over 40 years old globally. 89% of the cases seek treatment for symptomatic early stage prolapse. Despite the high prevalence and the progression of POP over time, patients c...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
MPRD
Innovative, minimally invasive Medical Prostatic Retraction...
5M€
Cerrado
Endosolve
She Sense: an accurate and non-invasive test that enables si...
2M€
Cerrado
PTQ-14-06757
Inclusión del cribado de la preeclampsia al estudio prenatal...
80K€
Cerrado
PID2019-108970RB-I00
EFICACIA Y SEGURIDAD DE LA TERAPIA FOTODINAMICA EN FISTULA A...
28K€
Cerrado
DPI2010-18316
MEJORA DE LAS CARACTERISTICAS FUNCIONALES DE LOS INSTRUMENTO...
12K€
Cerrado
Duración del proyecto: 22 meses
Fecha Inicio: 2023-11-20
Fecha Fin: 2025-09-30
Líder del proyecto
ESCALA MEDICAL LTD
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
5M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Pelvic Organ Prolapse (POP) affects nearly 50% of women over 40 years old globally. 89% of the cases seek treatment for symptomatic early stage prolapse. Despite the high prevalence and the progression of POP over time, patients currently cannot be offered a repair solution until the condition worsens enough for surgical intervention. However, the surgical interventions of prolapse have several side effects like prolonged recovery, pelvic pain and relapses of POP. Escala Medical has developed a minimally invasive and incision-free repair intervention for early-stage POP repair - Apyx. Apyx is the first medical device for treating early stage prolapse, regaining quality of life and prevention of prolapse deterioration for the vast majority, currently un-addressed, POP sufferers. The EIC project will finalize the development of Apyx, conduct clinical trials, and support scale-up and commercialization activities.